This phase Ib trial is trying to understand how safe and tolerable a type of targeted therapy is for the treatment of several different types of cancer.
This trial is treating multiple types of cancer including advanced urothelial carcinoma (UC), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer, colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a dose escalation and expansion study. In the dose escalation phase, eligible patients will be assigned to receive either 20mg, 40mg or 60mg of oral cabozantinib in combination with a standard dose of atezolizumab. Patients enrolled in the expansion phase will be assigned to a relevant cohort based on their diagnosis and treatment history, and will receive a recommended phase 2 dose of cabozantinib in combination with atezolizumab.
Recruiting Hospitals Read More